Inicio>>Signaling Pathways>> Chromatin/Epigenetics>> Epigenetic Reader Domain>>IACS-9571 (ASIS-P040)

IACS-9571 (ASIS-P040) (Synonyms: ASIS-P040)

Catalog No.GC33042

IACS-9571 (ASIS-P040) es un inhibidor potente y selectivo de TRIM24 y BRPF1, con una IC50 de 8 nM para TRIM24, y Kds de 31 nM y 14 nM para TRIM24 y BRPF1, respectivamente.

Products are for research use only. Not for human use. We do not sell to patients.

IACS-9571 (ASIS-P040) Chemical Structure

Cas No.: 1800477-30-8

Tamaño Precio Disponibilidad Cantidad
1mg
110,00 $
Disponible
5mg
321,00 $
Disponible
10mg
597,00 $
Disponible
50mg
2.068,00 $
Disponible
100mg
3.033,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

IACS-9571 is a potent and selective inhibitor of TRIM24 and BRPF1, with IC50 of 8 nM for TRIM24, and Kds of 31 nM and 14 nM for TRIM24 and BRPF1, respectively.

IACS-9571 shows excellent cellular potency with EC50 of 50 nM. IACS-9571 (1 μM) has potent activities against a panel of 32 bromodomains. IACS-9571 is a selective dual TRIM24/BRPF1 inhibitor (Kd = 1.3/2.1 nM) with 9- and 21-fold selectivity against BRPF2 and BRPF3, respectively. IACS-9571 does not interact with the BET sub-family of bromodomains, displaying greater than 7,700-fold selectivity versus BRD4(1, 2) relative to TRIM24[1].

[1]. Palmer WS, et al. Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor. J Med Chem. 2016 Feb 25;59(4):1440-54.

Reseñas

Review for IACS-9571 (ASIS-P040)

Average Rating: 5 ★★★★★ (Based on Reviews and 15 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for IACS-9571 (ASIS-P040)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.